TMO
Thermo Fisher Scientific Inc.
- EBITDA, 2025
- $10.5B
- YoY, 2025
- +0.8%
- 5-year CAGR
- +0.8%
- 10-year CAGR
- +10.1%
EBITDA
EBITDA by fiscal year
| Period | EBITDA | YoY |
|---|---|---|
| 2025 | $10.5B | +0.8% |
| 2024 | $10.4B | +1.8% |
| 2023 | $10.3B | −12.8% |
| 2022 | $11.8B | −6.7% |
| 2021 | $12.6B | +24.7% |
| 2020 | $10.1B | +47.3% |
| 2019 | $6.9B | +13.6% |
| 2018 | $6.1B | +21.2% |
| 2017 | $5.0B | +18.4% |
| 2016 | $4.2B | +4.8% |
| 2015 | $4.0B | −3.9% |
| 2014 | $4.2B | +60.5% |
| 2013 | $2.6B | +5.8% |
| 2012 | $2.5B | +16.8% |
| 2011 | $2.1B | +9.5% |
| 2010 | $1.9B | +9.2% |
| 2009 | $1.8B | −12.7% |
| 2008 | $2.0B | +16.8% |
| 2007 | $1.7B | — |